The antibody that stays off in healthy tissue and switches on inside the tumor.
CytomX Therapeutics builds antibody drugs that carry their own address label. Most cancer antibodies are engineered to recognize a molecular target - a protein that sits on the surface of a tumor cell. The problem is that many of the best targets also appear on healthy tissue, which is why some of the most promising cancer antibodies are simply too toxic to use. CytomX's answer is not a new target. It is an off switch.
The company's proprietary PROBODY platform attaches a masking peptide to an antibody and ties it on with a protease-cleavable linker. In healthy tissue the mask blocks the antibody from binding to anything. Inside the tumor microenvironment, where cancer-associated protease enzymes are unusually active, those enzymes cut the linker, the mask falls away, and the drug becomes active exactly where it is needed. The tumor, in effect, hands the drug the key to its own lock.
Founded in 2008 on protein-engineering science from the University of California, Santa Barbara, and headquartered in South San Francisco, CytomX has spent more than fifteen years turning that single masking idea into a clinical pipeline that now spans three distinct drug classes - antibody-drug conjugates, T-cell engagers and cytokines - all governed by the same conditional-activation principle.
A PROBODY therapeutic behaves like a prodrug for antibodies - inactive until the tumor unlocks it.
In oncology, the highest-value targets are often widely expressed - present on tumors but also on healthy cells. A conventional antibody cannot tell the difference, so it attacks both. That collateral damage caps the dose, and a capped dose caps the benefit.
By keeping the drug masked everywhere except the tumor, CytomX aims to widen the therapeutic window - the gap between a dose that works and a dose that harms. That reframing puts targets like EpCAM, long considered too dangerous to drug, back in play.
The clearest test of that thesis is EpCAM, an antigen so broadly present on healthy epithelial tissue that direct antibody approaches historically failed on safety. CytomX's lead program, the masked antibody-drug conjugate CX-2051, targets exactly that molecule in metastatic colorectal cancer - and its interim Phase 1 data offered an early signal that conditional activation may change the calculus.
"PROBODY therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues."
CytomX's wholly owned programs apply conditional activation across antibody-drug conjugates, cytokines and T-cell engagers.
*The ~28% overall response rate reflects interim Phase 1 data reported in 2025 and is approximate. Clinical results are preliminary and subject to change as trials progress.
CytomX advances wholly owned candidates - CX-2051 and CX-801 - through the clinic toward potential approval and commercialization, capturing full value if they succeed.
It partners the PROBODY platform with large pharma in exchange for upfront payments, research funding, milestones and royalties - turning the masking technology into recurring collaboration revenue.
The ultimate users are cancer patients in colorectal and melanoma trials; the direct commercial customers are five global pharmaceutical companies licensing the technology.
CytomX sits in the fast-moving field of conditionally activated and next-generation targeted biologics, alongside companies such as Janux, Xilio and Werewolf Therapeutics, and within the broader wave of antibody-drug conjugate and T-cell engager developers. Its differentiator is not any single molecule but a reusable engineering method - one validated by the breadth of pharma partners willing to build on it.
Each collaboration applies CytomX's masking technology to the partner's own targets and modalities.
These deals do more than fund the company. They validate the core bet: that conditional activation is broadly useful across oncology, not confined to a single drug or disease. For a platform company, a partner roster is a form of peer review.
President and CEO, and chairman of the board. Joined in December 2010 as chief business officer and became CEO in August 2011. He brings more than 25 years across biotech R&D, business development and general management, with prior roles at Millennium Pharmaceuticals and SGX Pharmaceuticals.
The masking concept traces to professor Patrick Daugherty's protein-engineering research. Co-founders Nancy Stagliano - an early CEO - and Frederick Gluck helped translate the academic insight into a company in 2008.
The name "PROBODY" fuses "prodrug" and "antibody" - the medicine stays inactive until the tumor unmasks it.
The founding science came out of UC Santa Barbara, where protein engineering seeded the whole masking idea.
EpCAM was long dismissed as too toxic to target. CytomX's lead ADC is a direct test of whether masking changes that.
The same masking principle powers an ADC, a T-cell engager and a cytokine - very different weapons, one control system.
CEO Sean McCarthy describes joining in 2010 when the company was barely formed - and stayed to take it public.